GNI Group (JP:2160) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GNI Group Ltd. has announced that their subsidiary GYRE Pharmaceuticals’ new drug, Avatrombopag Maleate Tablets, for treating thrombocytopenia in chronic liver disease patients, has been approved by China’s National Medical Products Administration. This addition expands the company’s portfolio, which includes treatments for rare diseases, although it is expected to have a minor impact on the fiscal year’s consolidated financial results.
For further insights into JP:2160 stock, check out TipRanks’ Stock Analysis page.